Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.

Journal of managed care & specialty pharmacy - 1 Jul 2015

Johnson Samuel G, Gruntowicz Don, Chua Theresa, Morlock Robert J

Abstract excerpt

BACKGROUND: Dual antiplatelet therapy is an established standard of care for patients with acute coronary syndrome (ACS) to reduce thrombotic risk. Reduced CYP2C19 activity impairs clopidogrel bio-activation and increases risk of adverse clinical outcomes. Patients with poor and intermediate CYP2C19 metabolizers treated with clopidogrel incur higher cardiovascular event rates, including myocardial infarction,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Adenosine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Models, Economic

Share to Percutaneous Coronary Intervention

Share to Prasugrel Hydrochloride

Share to Ticagrelor

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 26108379
DOI: 10.18553/jmcp.2015.21.7.552
PMCID: PMC10398109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.PMID 26108379Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Semantic proximity Read ↗

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Semantic proximity Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Semantic proximity Read ↗

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.Semantic proximity Read ↗

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Semantic proximity Read ↗

Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.Semantic proximity Read ↗

Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.Semantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary InterventionSemantic proximity Read ↗

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.